Package Leaflet: Information for the User
Apixaban Accord 2.5 mg film-coated tablets EFG
apixaban
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack and other information
Apixaban Accord contains the active substance apixaban and belongs to a group of medicines called anticoagulants. This medicine helps to prevent the formation of blood clots by blocking Factor Xa, an important element in the blood clotting process.
Apixaban Accord is used in adults:
Do not take Apixaban Accord
Warnings and precautions
Tell your doctor, pharmacist, or nurse before taking this medicine if you have any of these conditions:
This medicine will be used with caution in patients with signs of altered liver function
Be careful with Apixaban Accord
If you need to undergo surgery or a procedure that may cause bleeding, your doctor will tell you to temporarily stop taking this medicine for a while. If you are not sure if a procedure may cause bleeding, consult your doctor.
Children and adolescents
Apixaban Accord is not recommended for use in children and adolescents under 18 years of age.
Using Apixaban Accord with other medicines
Tell your doctor, pharmacist, or nurse if you are using, have recently used, or might use other medicines.
Some medicines may increase the effects of Apixaban Accord, and some medicines may decrease its effects. Your doctor will decide if you should be treated with Apixaban Accord if you are taking these medicines and if you should be kept under closer observation.
The following medicines may increase the effects of Apixaban Accord and increase the risk of unwanted bleeding:
The following medicines may reduce the ability of Apixaban Accord to prevent blood clot formation.
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
The effects of this medicine on pregnancy and the fetus are not known. You should not take this medicine if you are pregnant. Tell your doctor immediatelyif you become pregnant while taking this medicine.
It is not known if Apixaban Accord is excreted in human milk. Ask your doctor or pharmacist for advice before taking this medicine during breastfeeding. They will tell you whether to stop breastfeeding or whether to stop or not start taking Apixaban Accord.
Driving and using machines
Apixaban Accord has no influence on the ability to drive or use machines.
Apixaban Accord contains lactose (a type of sugar) and sodium.
If your doctor has told you that you have an intolerance to some sugars, talk to them before taking this medicine.
This medicine contains less than 1 mmol of sodium (23 mg) per tablet, which is essentially "sodium-free".
Follow exactly the administration instructions of this medicine given by your doctor or pharmacist. If you are not sure, ask your doctor, pharmacist, or nurse.
Dosage
Take the tablet with water. Apixaban Accord can be taken with or without food.
Try to take the tablets at the same time every day to achieve a better treatment effect.
If you have difficulty swallowing the tablet whole, talk to your doctor about other possible ways to take Apixaban Accord. The tablet can be crushed and mixed with water, 5% glucose in water, apple juice, or apple puree, immediately before taking it.
Instructions for crushing:
If necessary, your doctor may also administer the crushed Apixaban Accord tablet mixed in 60 ml of water or 5% glucose in water through a nasogastric tube.
Take Apixaban Accord according to the following recommendations:
To prevent the formation of blood clots in hip or knee replacement surgery.
The recommended dose of Apixaban Accord is one 2.5 mg tablet twice a day.
For example, take one tablet in the morning and one in the evening.
You should take the first tablet between 12 and 24 hours after surgery.
If you have undergone major hipsurgery, you will generally take the tablets for a period of 32 to 38 days.
If you have undergone major kneesurgery, you will generally take the tablets for a period of 10 to 14 days.
To prevent the formation of a blood clot in the heart in patients with an irregular heartbeat and at least one additional risk factor.
The recommended dose of Apixaban Accord is one 5 mg tablet twice a day.
The recommended dose is one 2.5 mg tablet twice a day if:
The recommended dose is one tablet twice a day, for example, take one tablet in the morning and one in the evening. Your doctor will tell you how long you should continue the treatment.
To treat blood clots in the veins of the legs and in the blood vessels of the lungs
The recommended dose is two 5 mg tabletstwice a day for the first 7 days, for example, two tablets in the morning and two tablets in the evening. After 7 days, the recommended dose is one 5 mg tablettwice a day, for example, one tablet in the morning and one in the evening.
To prevent blood clots from recurring after 6 months of treatment
The recommended dose is one 2.5 mg tablet twice a day, for example, one tablet in the morning and one in the evening.
Your doctor will tell you how long you should continue the treatment.
Your doctor may change your anticoagulant treatment as follows:
Stop taking Apixaban Accord. Start treatment with other anticoagulant medicines (e.g., heparin) at the time you would take the next Apixaban Accord tablet.
Stop taking other anticoagulant medicines. Start treatment with Apixaban Accord at the time you would take the next dose of the other anticoagulant medicine, and then continue as usual.
Stop taking the medicine that contains a Vitamin K antagonist. Your doctor will need to perform blood tests and tell you when to start taking Apixaban Accord.
If your doctor tells you to start taking a medicine that contains a Vitamin K antagonist, continue taking Apixaban Accord for at least 2 days after your first dose of the medicine that contains a Vitamin K antagonist. Your doctor will need to perform blood tests and tell you when to stop taking Apixaban Accord.
Patients undergoing cardioversion
If your heartbeat needs to be restored through a process called cardioversion, take this medicine at the times your doctor indicates to prevent blood clots in the blood vessels of the brain and other blood vessels in the body.
If you take more Apixaban Accord than you should
Tell your doctor immediatelyif you have taken a dose greater than the prescribed dose of Apixaban Accord. Take the medicine package to your doctor, even if there are no tablets left.
If you take more Apixaban Accord than the recommended dose, you may increase the risk of bleeding. If bleeding occurs, surgery, blood transfusions, or other treatments that can reverse the anti-factor Xa activity may be necessary.
If you forget to take Apixaban Accord
If you are not sure what to do or if you forget to take more than one dose,ask your doctor, pharmacist, or nurse.
If you stop taking Apixaban Accord
Do not stop taking this medicine without talking to your doctor first, because the risk of developing a blood clot may be greater if you stop the treatment too soon.
If you have any further questions on the use of this product, ask your doctor, pharmacist, or nurse.
Like all medicines, Apixaban Accord can cause adverse effects, although not all people suffer from them. Apixaban Accord can be administered for three different diseases. The known adverse effects and the frequency at which they occur may be different and are therefore indicated separately below. For these conditions, the most frequent adverse effect of this medication is bleeding, which can put the patient's life at risk and requires immediate medical attention.
The following adverse effects have been reported when taking Apixaban Accord to prevent the formation of blood clots in hip or knee replacement surgeries.
Frequent Adverse Effects (may affect up to 1 in 10 people)
Uncommon Adverse Effects (may affect up to 1 in 100 people)
Rare Adverse Effects (may affect up to 1 in 1,000 people)
Frequency Not Known (cannot be estimated from available data)
The following adverse effects have been reported when taking Apixaban Accord to prevent the formation of blood clots in the heart in patients with irregular heart rhythm and at least one additional risk factor.
Frequent Adverse Effects (may affect up to 1 in 10 people)
Uncommon Adverse Effects (may affect up to 1 in 100 people)
Rare Adverse Effects (may affect up to 1 in 1,000 people)
Very Rare Adverse Effects (may affect up to 1 in 10,000 people)
Frequency Not Known (cannot be estimated from available data)
The following adverse effects have been reported when taking Apixaban Accord to treat or prevent blood clots from recurring in the veins of the legs and in the blood vessels of the lungs.
Frequent Adverse Effects (may affect up to 1 in 10 people)
Uncommon Adverse Effects (may affect up to 1 in 100 people)
Rare Adverse Effects (may affect up to 1 in 1,000 people)
Bleeding:
Frequency Not Known (cannot be estimated from available data)
Reporting of Adverse Effects
If you experience any type of adverse effect, consult your doctor, pharmacist, or nurse, even if it is a possible adverse effect that is not listed in this leaflet. You can also report them directly through the national reporting system included in Appendix V. By reporting adverse effects, you can contribute to providing more information on the safety of this medication.
Keep this medication out of sight and reach of children.
Do not use this medication after the expiration date shown on the packaging and on each blister, after "EXP". The expiration date is the last day of the month indicated.
This medication does not require special storage conditions.
Medicines should not be disposed of through wastewater or household waste. Ask your pharmacist how to dispose of the packaging and any unused medication. This will help protect the environment.
Composition of Apixaban Accord
Appearance of the Product and Package Contents
The film-coated tablets are round, biconvex, yellow in color, and have "IU1" engraved on one side, and are smooth on the other.
They are available in aluminum-PVC/PVdC blisters of 10, 14, 20, 28, 56, 60, 100, 112, 168, and 200 film-coated tablets.
They are available in single-dose aluminum-PVC/PVdC blisters of 10 x 1, 20 x 1, 28 x 1, 56 x 1, 60 x 1, 100 x 1, and 168 x 1 film-coated tablets.
HDPE bottle with a child-resistant polypropylene cap with 60, 100, 168, 180, 200, and 1,000 film-coated tablets.
Not all pack sizes may be marketed.
Patient Information Card: Handling of Information
Inside the Apixaban Accord packaging, along with the leaflet, you will find a Patient Information Card or your doctor may give you a similar card.
This Patient Information Card includes useful information for you and will alert other doctors that you are being treated with Apixaban Accord. You must keep this card with you at all times.
Marketing Authorization Holder and Manufacturer
Marketing Authorization Holder
Accord Healthcare S.L.U.
World Trade Center, Moll de Barcelona, s/n,
Edifici Est, 6a Planta,
08039 Barcelona,
Spain
Manufacturer
LABORATORI FUNDACIÓ DAU
C/ C, 12-14 Pol. Ind. Zona Franca, Barcelona,
08040 Barcelona, Spain
Accord Healthcare Polska Sp. z.o.o.
ul.Lutomierska 50,
95-200, Pabianice,
Poland
Pharmadox Healthcare Limited
KW20A Kordin Industrial Park,
Paola PLA 3000, Malta
Date of the Last Revision of this Leaflet:{MM/YYYY}.
Detailed information on this medication is available on the European Medicines Agency website http://www.ema.europa.eu/.